Impact of hepatitis C cure on risk of mortality and morbidity in people with HIV after antiretroviral therapy initiation.
Journal
AIDS (London, England)
ISSN: 1473-5571
Titre abrégé: AIDS
Pays: England
ID NLM: 8710219
Informations de publication
Date de publication:
01 08 2023
01 08 2023
Historique:
medline:
17
7
2023
pubmed:
18
5
2023
entrez:
18
5
2023
Statut:
ppublish
Résumé
Hepatitis C virus (HCV) co-infection is associated with increased morbidity and mortality in people with HIV (PWH). Sustained virological response (SVR) decreases the risk of HCV-associated morbidity. We compared mortality, risk of AIDS-defining events, and non-AIDS nonliver (NANL) cancers between HCV-co-infected PWH who reached SVR and mono-infected PWH. Adult PWH from 21 cohorts in Europe and North America that collected HCV treatment data were eligible if they were HCV-free at the time of ART initiation. Up to 10 mono-infected PWH were matched (on age, sex, date of ART start, HIV acquisition route, and being followed at the time of SVR) to each HCV-co-infected PWH who reached SVR. Cox models were used to estimate relative hazards (hazard ratio) of all-cause mortality, AIDS-defining events, and NANL cancers after adjustment. Among 62 495 PWH, 2756 acquired HCV, of whom 649 reached SVR. For 582 of these, at least one mono-infected PWH could be matched, producing a total of 5062 mono-infected PWH. The estimated hazard ratios comparing HCV-co-infected PWH who reached SVR with mono-infected PWH were 0.29 [95% confidence interval (CI) 0.12-0.73] for mortality, 0.85 [0.42-1.74] for AIDS-defining events, and 1.21 [0.86-1.72] for NANL cancer. PWH who reached SVR a short time after HCV acquisition were not at higher risk of overall mortality compared with mono-infected PWH. However, the apparent higher risk of NANL cancers in HCV-co-infected PWH who reached SVR after a DAA-based treatment compared with mono-infected PWH, though compatible with a null association, suggests a need for monitoring of those events following SVR.
Identifiants
pubmed: 37199601
doi: 10.1097/QAD.0000000000003594
pii: 00002030-202308010-00010
doi:
Substances chimiques
Antiviral Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1573-1581Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Westbrook RH, Dusheiko G. Natural history of hepatitis C . J Hepatol 2014; 61: (1 Suppl): S58–S68.
Platt L, Easterbrook P, Gower E, McDonald B, Sabin K, McGowan C, et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis . Lancet Infect Dis 2016; 16:797–808.
World Health Organization. Global hepatitis report 2017 [Internet]. Geneva: World Health Organization; 2017. Available at: https://apps.who.int/iris/handle/10665/255016 [Accessed 31 December 2020]
Pol S, Lamorthe B, Thi NT, Thiers V, Carnot F, Zylberberg H, et al. Retrospective analysis of the impact of HIV infection and alcohol use on chronic hepatitis C in a large cohort of drug users . J Hepatol 1998; 28:945–950.
Soto B, Sánchez-Quijano A, Rodrigo L, del Olmo JA, García-Bengoechea M, Hernández-Quero J, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis . J Hepatol 1997; 26:1–5.
Ingiliz P, Rockstroh JK. Natural history of liver disease and effect of hepatitis C virus on HIV disease progression . Curr Opin HIV AIDS 2015; 10:303–308.
Rockstroh JK, Mohr R, Behrens G, Spengler U. Liver fibrosis in HIV: which role does HIV itself, long-term drug toxicities and metabolic changes play? . Curr Opin HIV AIDS 2014; 9:365–370.
Crowell TA, Gebo KA, Balagopal A, Fleishman JA, Agwu AL, Berry SA. Impact of hepatitis co-infection on hospitalization rates and causes in a multi-center cohort of persons living with HIV . J Acquir Immune Defic Syndr 19992014; 65:429–437.
Meijide H, Pértega S, Rodríguez-Osorio I, Castro-Iglesias Á, Baliñas J, Rodríguez-Martínez G, et al. Increased incidence of cancer observed in HIV/hepatitis C virus-coinfected patients versus HIV-monoinfected . AIDS 2017; 31:1099–1107.
Wang Q, De Luca A, Smith C, Zangerle R, Sambatakou H, Bonnet F, et al. Chronic hepatitis B and C virus infection and risk for non-Hodgkin lymphoma in HIV-infected patients: a cohort study . Ann Intern Med 2017; 166:9–17.
Kovari H, Ledergerber B, Cavassini M, Ambrosioni J, Bregenzer A, Stöckle M, et al. Swiss HIV Cohort Study. High hepatic and extrahepatic mortality and low treatment uptake in HCV-coinfected persons in the Swiss HIV cohort study between 2001 and 2013 . J Hepatol 2015; 63:573–580.
May MT, Justice AC, Birnie K, Ingle SM, Smit C, Smith C, et al. Injection drug use and hepatitis C as risk factors for mortality in HIV-infected individuals: the Antiretroviral Therapy Cohort Collaboration . J Acquir Immune Defic Syndr 2015; 69:348–354.
Antiretroviral Therapy Cohort Collaboration. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies . Lancet HIV 2017; 4:e349–e356.
Klein MB, Rollet-Kurhajec KC, Moodie EEM, Yaphe S, Tyndall M, Walmsley S, et al. Mortality in HIV-hepatitis C co-infected patients in Canada compared to the general Canadian population (2003-2013) . AIDS 2014; 28:1957–1965.
Morlat P, Roussillon C, Henard S, Salmon D, Bonnet F, Cacoub P, et al. ANRS EN20 Mortalité 2010 Study Group. Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000 . AIDS 2014; 28:1181–1191.
Sanmartín R, Tor J, Sanvisens A, López JJ, Jou A, Muga R, et al. Progression of liver fibrosis in HIV/hepatitis C virus-coinfected individuals on antiretroviral therapy with early stages of liver fibrosis at baseline . HIV Med 2014; 15:203–212.
Gjærde LI, Shepherd L, Jablonowska E, Lazzarin A, Rougemont M, Darling K, et al. Trends in incidences and risk factors for hepatocellular carcinoma and other liver events in HIV and hepatitis C virus-coinfected individuals from 2001 to 2014: a multicohort study . Clin Infect Dis 2016; 63:821–829.
Rockstroh JK, Nelson M, Katlama C, Lalezari J, Mallolas J, Bloch M, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a nonrandomised, open-label trial . Lancet HIV 2015; 2:e319–e327.
Chalouni M, Pol S, Sogni P, Fontaine H, Lacombe K, Jean-Marc-Lacombe null, et al. Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to nonliver-related death . J Hepatol 2020; 74:37–47.
Nahon P, Bourcier V, Layese R, Audureau E, Cagnot C, Marcellin P, et al. ANRS CO12 CirVir Group. Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications . Gastroenterology 2017; 152:142.e2–156.e2.
El-Serag HB, Kanwal F, Richardson P, Kramer J. Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection . Hepatology 2016; 64:130–137.
Butt AA, Yan P, Simon TG, Abou-Samra AB. Effect of paritaprevir/ritonavir/ombitasvir/dasabuvir and ledipasvir/sofosbuvir regimens on survival compared with untreated hepatitis c virus-infected persons: results from ERCHIVES . Clin Infect Dis 2017; 65:1006–1011.
van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis . JAMA 2012; 308:2584–2593.
van der Meer AJ, Berenguer M. Reversion of disease manifestations after HCV eradication . J Hepatol 2016; 65: (1 Suppl): S95–S108.
May MT, Ingle SM, Costagliola D, Justice AC, de Wolf F, Cavassini M, et al. Antiretroviral Cohort Collaboration. Cohort profile: Antiretroviral Therapy Cohort Collaboration (ART-CC) . Int J Epidemiol 2014; 43:691–702.
Heathcote EJ. Treatment considerations in patients with hepatitis C and cirrhosis . J Clin Gastroenterol 2003; 37:395–398.
Fried MW. Side effects of therapy of hepatitis C and their management . Hepatology 2002; 36: (5 Suppl 1): S237–S244.
Portocarrero Nuñez JA, Gonzalez-Garcia J, Berenguer J, Gallego MJV, Loyarte JAI, Metola L, et al. the Cohort of the Spanish HIV Research Network (CoRIS). Impact of co-infection by hepatitis C virus on immunological and virological response to antiretroviral therapy in HIV-positive patients . Medicine (Baltimore) 2018; 97:e12238.
Taye S, Lakew M. Impact of hepatitis C virus co-infection on HIV patients before and after highly active antiretroviral therapy: an immunological and clinical chemistry observation, Addis Ababa, Ethiopia . BMC Immunol 2013; 14:23.
Weis N, Lindhardt BO, Kronborg G, Hansen ABE, Laursen AL, Christensen PB, et al. Impact of hepatitis C virus coinfection on response to highly active antiretroviral therapy and outcome in HIV-infected individuals: a nationwide cohort study . Clin Infect Dis 2006; 42:1481–1487.
Sullivan PS, Hanson DL, Teshale EH, Wotring LL, Brooks JT. Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy . AIDS 2006; 20:1171–1179.
Law WP, Duncombe CJ, Mahanontharit A, Boyd MA, Ruxrungtham K, Lange JMA, et al. Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort . AIDS 2004; 18:1169–1177.
Santin M, Mestre M, Shaw E, Barbera MJ, Casanova A, Niubo J, et al. Impact of hepatitis C virus coinfection on immune restoration during successful antiretroviral therapy in chronic human immunodeficiency virus type 1 disease . Eur J Clin Microbiol Infect Dis 2008; 27:65–73.
Stafford KA, Rikhtegaran Tehrani Z, Saadat S, Ebadi M, Redfield RR, Sajadi MM. Long-term follow-up of elite controllers . Medicine (Baltimore) 2017; 96:e7348.
Saracino A, Bruno G, Scudeller L, Ladisa N, de Gennaro N, Allegrini M, et al. CD4 and CD4/CD8 ratio progression in HIV-HCV infected patients after achievement of SVR . J Clin Virol 2016; 81:94–99.
Cacoub P, Saadoun D. Extrahepatic manifestations of chronic HCV infection . N Engl J Med 2021; 384:1038–1052.
Mahale P, Engels EA, Li R, Torres HA, Hwang LY, Brown EL, Kramer JR. The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection . Gut 2018; 67:553–561.
Wang W, Lo Re V, Guo Y, Xiao H, Brown J, Park H. Impact of hepatitis C virus treatment on the risk of nonhepatic cancers among hepatitis C virus-infected patients in the US . Aliment Pharmacol Ther 2020; 52:1592–1602.
Mocroft A, Lundgren J, Gerstoft J, Rasmussen LD, Bhagani S, Aho I, et al. EuroSIDA Study. Clinical outcomes in persons coinfected with human immunodeficiency virus and hepatitis C virus: impact of hepatitis C virus treatment . Clin Infect Dis 2020; 70:2131–2140.
Ghany MG, Strader DB, Thomas DL, Seeff LB. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update . Hepatology 2009; 49:1335–1374.